drugset / Trial / NCT02083315

Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

NCT02083315

Phase 1 Completed 30 enrolled Trevena Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is designed to compare TRV130 to placebo and morphine to learn about its effects on pain relief and side effects.

Timeline

Start
2013-07
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 10 mg Intravenous
Subject Oliceridine Other / unclassified 1.5 mg Intravenous
Subject Oliceridine Other / unclassified 3 mg Intravenous
Subject Oliceridine Other / unclassified 4.5 mg Intravenous

Indications

No indication recorded.